Cofetuzumab pelidotin (PF-06647020) is an experimental cancer therapy targeting protein tyrosine kinase 7 (PTK7), a protein found in certain cancers. It combines a PTK7-specific antibody with Auristatin-0101 (Aur0101), a powerful drug that disrupts cell division, and a cleavable valine-citrulline linker. This design allows targeted delivery of the cytotoxic agent to cancer cells.
Key Features
- Targeted Therapy: Binds specifically to PTK7, a receptor found in cancers like ovarian, breast, and non-small cell lung cancers.
- Mechanism of Action: After binding to PTK7-expressing cells, the ADC enters the cell and releases Aur0101, which disrupts microtubules, halting cell division and causing cell death.
- Precision Treatment: Focuses on cancer-specific receptors to limit damage to healthy tissues.
Applications
- Ovarian Cancer: Potential treatment for platinum-resistant ovarian cancers with high PTK7 expression.
- Breast Cancer: Investigated for use in triple-negative breast cancer (TNBC), a subtype lacking other targeted therapies.
- Lung Cancer: Explored as a treatment for non-small cell lung cancer (NSCLC) with PTK7 expression.
- Targeted Therapy Research: A model for advancing ADC technologies in oncology.
- Precision Oncology: Helps develop patient-specific treatments by targeting PTK7.
- Preclinical Studies: A valuable tool for studying PTK7-related cancer pathways.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.